ArticleJournal of blood medicine2012
Ethical and legal considerations regarding the ownership and commercial use of human biological materials and their derivatives.
Article in Journal of blood medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Women's perceptions of placenta donation for research purposes: a cross-sectional study from the MENA region.Philosophy, ethics, and humanities in medicine : PEHM · 2026Article
- Orthobiologics Revisited: A Concise Perspective on Regenerative Orthopedics.Current issues in molecular biology · 2025Review
- Emerging Ethical Challenges in Manufacturing of Cell-Based Medicines.Advances in experimental medicine and biology · 2025Review
- A Perspective on the Characterization of Early Neural Progenitor Cell-Derived Extracellular Vesicles for Targeted Delivery to Neuroblastoma Cells.Neurochemical research · 2024Article
- SDPR expression in human trabecular meshwork and its potential role in racial disparities of glaucoma.Scientific reports · 2024Article
- Next-Gen Dual Transcriptomics for Adult Extrapulmonary Tuberculosis Biomarkers and Host-Pathogen Interplay in Human Cells: A Strategic Review.Indian journal of microbiology · 2024Review
- WHO CAN USE YOUR CELLS OR TISSUES FOR SCIENTIFIC RESEARCH?Frontiers for young minds · 2024Article
- Tissue and Cell Donation: Recommendations From an International Consensus Forum.Transplantation direct · 2023Article
- 3D Modeling and Printing in Congenital Heart Surgery: Entering the Stage of Maturation.Frontiers in pediatrics · 2021Review
- From Donor to the Lab: A Fascinating Journey of Primary Cell Lines.Frontiers in cell and developmental biology · 2021Review
- Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain.Frontiers in cell and developmental biology · 2021Article
- Research Ethics Committees in Laboratory Medicine.EJIFCC · 2020Review
- Biobanking in health care: evolution and future directions.Journal of translational medicine · 2019Review
- Bioethics in Practice: The Ethics Surrounding the Use of Donor Milk.Ochsner journal · 2018Article
- A perpetual source of DNA or something really different: ethical issues in the creation of cell lines for African genomics research.BMC medical ethics · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article considers some of the ethical and legal issues relating to the ownership and use - including for commercial purposes - of biological material and products derived from humans. The discussion is divided into three parts: after first examining the general notion of ownership, it moves to the particular case of possible commercial use, and finally reflects on the case in point in the light of the preceding considerations. Units of cord blood donated altruistically for transplantation and which are found unsuitable for storage and transplantation, or which become unsuitable while stored in biobanks, are taken as an example. These cord-blood units can be discarded together with other biological waste, or they can be used for research or the development of blood-derived products such as platelet gel. Several ethical questions (eg, informed consent, property, distribution of profits, and others) arise from these circumstances. In this regard, some criteria and limits to use are proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.